Safety and Effectiveness of Evexomostat Combined With a PI3K or AKT Inhibitor Plus Fulvestrant for Adults With HR, HER2- Metastatic Breast Cancer Having PI3K Pathway Changes
Led by SynDevRx, Inc. · Updated on 2026-04-22
52
Participants Needed
10
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination treatment for men and post-menopausal women with hormone receptor positive HR, HER2-negative advanced or metastatic breast cancer that has specific alterations in the PI3K pathway, such as mutations in the PIK3CA gene, PTEN loss, or AKT1 mutation. This Phase 1b2, open-label pilot study aims to determine the safety of evexomostat combined with either alpelisib or capivasertib plus fulvestrant, measure the severity and number of hyperglycemic events, and assess the anti-tumor effects of these triplet therapies.
Participants will first receive evexomostat plus fulvestrant for 14 days before adding either alpelisib or capivasertib, depending on the oncologists choice, forming the triplet therapy. Treatment cycles last 28 days, and doses of evexomostat may be adjusted based on safety data. Patients may continue the triplet therapy for up to seven cycles, or longer if clinical benefit is observed, with ongoing safety and efficacy monitoring.
During the study, patients will undergo tumor assessments and monitoring of hyperglycemic events, glucose control, insulin resistance, and various biomarkers related to tumor and metabolic activity. Safety data, adverse events, and quality of life will be evaluated up to 42 to 48 months. Participants must attend scheduled visits and comply with fasting requirements on designated days. The study allows continuation of therapy until disease progression, unacceptable toxicity, or withdrawal.
CONDITIONS
Brief Title
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Research Team
D
David Browning
J
James M Shanahan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Investigational combination regimen (in trial)
Current-care regimen (external context)
What is it?
A combination regimen including Evexomostat (SDX-7320), a novel MetAP2 inhibitor, plus a PI3K or AKT inhibitor and fulvestrant, being evaluated in a clinical trial for patients with metastatic HR+/HER2-negative breast cancer and PI3K pathway alteration.
A currently recommended combination therapy using alpelisib (a PI3K inhibitor) plus fulvestrant for patients with HR+/HER2-negative metastatic breast cancer with a PI3K pathway alteration, following prior endocrine and CDK4/6 inhibitor therapy.
Role in the trial
The investigational regimen is the sole therapy studied in this clinical trial. All participants receive Evexomostat, PI3K or AKT inhibitor, and fulvestrant.
This combination is shown for external context; it was not evaluated as a comparator in this trial.
Primary use
Investigational therapy aimed at treating metastatic breast cancer in patients with PI3K pathway alteration after progression on endocrine therapy and CDK4/6 inhibitor therapy.
Approved and guideline-supported for metastatic HR+/HER2-negative breast cancer with PI3K mutation after endocrine therapy and CDK4/6 inhibitors.
How is it given or performed?
Evexomostat is administered with a PI3K or AKT inhibitor (alpelisib or capivasertib) and fulvestrant. Dosing is supervised by the protocol in a hospital or clinic setting; fasting and regular monitoring are required.
Alpelisib is given orally once daily, and fulvestrant as an intramuscular injection on a standard schedule. Regular blood sugar monitoring and clinical visits are part of routine care.
Evidence status
Ongoing clinical investigation; published results for Evexomostat combination are not yet established in this population.
Large randomized studies and clinical reviews support its use, with evidence of anti-tumor activity and improved progression-free survival in PI3K-mutated HR+/HER2-negative metastatic breast cancer.
Important limitations
The safety and efficacy profile of Evexomostat in combination with PI3K or AKT inhibitors and fulvestrant is not yet established. As an investigational regimen in a small early phase study, results may be limited by sample size and absence of direct comparator arms.
Alpelisib plus fulvestrant is associated with frequent hyperglycemia and other metabolic adverse events. Management requires careful monitoring and supportive care; tolerability and adherence may limit use in some patients.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adult male or postmenopausal female aged 18 years or older who has signed informed consent
Histologically or cytologically confirmed hormone receptor positive (HR+), HER2-negative breast cancer
Identified PI3K pathway alteration (PIK3CA mutation, PTEN loss, or AKT1 mutation) confirmed by FDA-approved test
Locally advanced or metastatic breast cancer with evidence of progressive disease after endocrine and CDK 4/6 inhibitor therapy
Measurable disease per RECIST v1.1 criteria or eligible for safety cohorts if only bone metastases
Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0 or 1
Screening fasting plasma glucose ≤140 mg/dL and HbA1c ≤6.4% (for alpelisib) or ≤8% (for capivasertib)
Body mass index (BMI) ≥20 kg/m2
Postmenopausal female defined by age, amenorrhea duration, or surgical status
Allowed prior fulvestrant treatment if eligible, excluding progression on fulvestrant monotherapy
Allowed prior mTOR, PI3K, or AKT inhibitor treatment if eligible
Allowed up to one prior chemotherapy for metastatic disease
Willing and able to arrive fasting (>8 hours) on designated days
Adequate bone marrow and organ function as specified by laboratory values
Able to take oral medications
You will not qualify if you...
Inflammatory breast cancer at screening
Known primary brain malignancy, active brain metastasis, or unstable central nervous system conditions
Known hypersensitivity to study drugs or their ingredients
Diagnosis of type 1 diabetes or uncontrolled type 2 diabetes or recent insulin use
Recent major or minor surgery without full recovery
Ongoing toxicities from prior cancer treatments not resolved to acceptable levels
Child Pugh score of B or C
Uncontrolled HIV infection
Recent radiotherapy without recovery
Concurrent or recent other malignancies except certain treated skin or cervical cancers
Gastrointestinal conditions affecting drug absorption
Documented or unresolved lung disease such as pneumonitis
Current use of certain medications that cannot be stopped prior to study
History of acute or chronic pancreatitis
Unresolved osteonecrosis of the jaw (for certain treatment groups)
History of severe skin reactions
Recent systemic corticosteroid use without recovery
Nursing or pregnant females
Recent participation in investigational studies
Severe or uncontrolled medical conditions contraindicating study participation
Inability to understand or comply with study instructions including fasting requirements
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Run-in Period
Duration - 14 days
Participants receive evexomostat plus fulvestrant before adding the additional study drugs.
1 baseline visit
Treatment
Duration - Up to 7 cycles of 28 days each
Participants receive the triplet therapy consisting of evexomostat plus either alpelisib or capivasertib and fulvestrant in 28-day cycles.
Repeated visits for each 28-day treatment cycle
Follow-up
Duration - Up to 42 months
Participants are monitored for safety, anti-tumor efficacy, and metabolic effects after treatment cycles.
Visits scheduled based on treatment and safety assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluating Safety, Dose, and Effects of BNT323 Combined With BNT327 in Advanced Breast Cancer Patients A Phase III Open-Label Two-Part Study
Phase 1 Study to Evaluate the Safety, Tolerability, and Distribution of 177LuLu-ABY-271 in Women with HER2-positive Metastatic Breast Cancer
Evaluating the TheraBionic P1 Device in Women with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer After Endocrine Therapy
Phase 1 Study of ERX-315 Given by IV Twice Weekly in Adults With Advanced Solid Tumors That Have Not Responded to Standard Treatments
Randomized Phase 3 Trial of HRS-8080 Versus Physician-Selected Treatments in Women With Advanced and Metastatic Breast Cancer After Endocrine Therapy
Phase I Open-Label Trial to Test Safety and Early Effectiveness of Autologous p95HER2.CAR-TECH2Me T Cells in Adults with Advanced HER2-Positive Breast, Gastric, Endometrial, and Other Selected Cancers
Phase III Study of FWD1802 Treatment for Women With ERHER2- Advanced or Metastatic Breast Cancer
Study of Multiple Combination Therapies with FWD1802 for Women with ER-positiveHER2-negative Advanced or Metastatic Breast Cancer
Phase II Study of SSGJ-612 Combined With HER2-Targeted Antibody-Drug Conjugate in Hormone Receptor-Positive, HER2-Low or Ultralow Metastatic Breast Cancer
Phase 3 Study Comparing ESG401 and Physicians Choice Chemotherapy for Adults with Advanced HRHER2- Breast Cancer After Chemotherapy Failure
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.